(48) showed that when Galectin-3 is expressed by prostate tumor cells, it can control the tumor growth and decrease the number of tumor infiltrated T cells, suggesting that this protein is the principal immunological checkpoint responsible of the failure of immunotherapy in advanced prostate cancer. The gene discussed is LGALS3; the disease is neoplasm.